Previous 10 | Next 10 |
3 Ways That World Events Cause Penny Stocks Movement When it comes to buying and selling penny stocks, world events are likely the main cause of market movement. Wars, natural disasters, and other geo-political, and economic events can all have a profound effect on both penny stocks a...
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2022 financial results after the U.S. financial mar...
Oncternal Therapeutics ( NASDAQ: ONCT ) on Thursday said it had entered into a clinical trial collaboration with AbbVie ( ABBV ) company Pharmacyclics to support its phase 3 lymphoma study. ONCT stock gained ~9% to $1.22 after hours. As per the terms of the...
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation of ZILO-301 in Q3 2022 and will also supply ibrutinib for the ...
The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this event. For further details see: Oncternal Therapeutics (ONCT) Investor Presentation -slideshow
The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this event. For further details see: onct
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell therapy programs will be highlighte...
Oncternal Therapeutics (NASDAQ:ONCT) said it will begin a phase 3 trial of ZILO-301, a combination of its experimental monocolonal antibody zilovertamab with Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) in Q3. The study, which will enroll ~250 people, will evaluate the potential bene...
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibru...
ONCT already has great data in MCL, but that data further improved as the Phase 2 study matured. I parse some of the results and compare them to previous data from current standard of care ibrutinib. Based on the entirety of its data, ONCT is initiating a Phase 3 MCL registrationa...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...